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Abstract
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small 
peptide (somatostatin analogue — SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine 
for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with 
overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. 
arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large 
bowel or the lung and many other tissues (so called diffuse neuroendocrine system). The goal of PRRT is irradiation of tumour 
cells, via direct binding into specific receptor, somatostatin receptors (SSTR) family, overexpressed on the cell membrane of 
the primary tumours as well as on the metastasis. Over many years of clinical use of PRRT with 90Y and current with 177Lu DOTA 
conjugated somatostatin analogues proved to be efficient therapy option for NETs, with tumour responses, base on radiological 
evaluation. Also, a clinical response with symptoms relief and improvement in quality of life based on standard EORTC ques-
tioners is seen. Additional, common NET biomarker reduction and, ultimately, an impact on overall survival (OS) of patients 
with advanced non-resectable often progressive NEN can be expected. PRRT with 90Y or 177Lu-labelled peptides is generally 
well tolerated by most of the patients. The acute side effects (Adverse Events — AEs) are usually mild; most of them are related 
to the co-administration of amino acids (AA), such as nausea and vomiting. Others are related to the radioisotopes, such as 
fatigue or the exacerbation of endocrine syndromes, which are very rarely and they occurs, only in patients with functional 
tumours and large tumours burden. Chronic and permanent damage has an effect on target organs, particularly the kidneys 
and the bone marrow, which are generally mild. Currently, when 177Lu DOTATATE is used, the potential risk to kidney damage 
is significantly reduced, compared to the previous usage of 90Y labelled analogues. Up to now, kidney and bone marrow toxicity 
limits the dose of radioactivity of PRRT. 
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Introduction
PRRT with radiolabeled somatostatin analogues (SSTA) 
is a reasonable option for treatment of non-resectable and/or 
metastasized, well/moderately differentiated, NETs [1–7]. The main 
goal of PRRT is to deliver the high dose of radiation to the tumour 
cells and a cross-fire effect that targeted nearby receptor-negative 
tumour cells, thus limiting the dose of irradiation of normal tissues. 
Radioisotope labelled synthetic somatostatin analogues (SST) 
are used by systemic administration with fractionated dose and in 
sequential cycles (usually 4–5) every 6 to 9 weeks [1, 2]. Currently, 
the potential risk of kidney and bone marrow damage limits the 
cumulative dose of radioactivity that may be administered. 
The volume reduction of tumour burden can be seen, when 
tumour masses are irradiated with adequate doses of high energetic 
electrons [3–9]. Tumour response is associated with high uptake 
of radioisotopes on somatostatin receptor scintigraphy with 99mTc 
or, more recently, with 68Ga-labeled octreotide/tate using PET tech-
nology [1, 2]. The therapeutic efficacy is related to a high affinity 
for somatostatin receptors subtype 2 (sst2) and moderate affinity 
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for subtype 5 (sst5). However, tumour dose does not depend di-
rectly only on the administered activity and the uptake versus time, 
namely on the amount of energy released. The response also de-
pends on tumour mass and biology of cancer cells with potential 
high resistant rate of tumour, even a high absorbed dose of energy 
deposition within cancer cells, due to high SSTR expression. Po-
tentially, smaller masses have higher chances of reduction, owing 
to a higher absorbed dose in the tumour. Another factor influencing 
tumour irradiation, and therefore, the response, is the choice of 
the radionuclide. Each of the β emitters currently used for therapy, 
177Lu and 90Y, shows some potential advantages. In particular, 90Y 
electrons are highly energetic (Emax 2.27 MeV, penetration range 
Rmax 11 mm, half-life T1/2 64 hours) and penetrating, leading to bet-
ter crossfire through the tumour, which is particularly valuable in 
larger tumours and when heterogeneous receptor and/or activity 
distribution exists. The shorter half-life of 90Y allows a higher dose 
rate. 177Lu, on the other hand, has lower energy and smaller particle 
range, allowing a better absorption probably in smaller tumours, 
also has less toxicity to bone marrow and kidney [1, 2].
90Y-octreotide [DOTATOC] was the first radiopeptide with beta 
emission used in PRRT; therefore, has been the most widely used 
in the first years of experience. Others peptides like 90Y DOTALAN 
(DOTA Lanreotide) or 90Y DOTATAE (DOTA Octreotate) were 
less common used in clinical practice. Unfortunately, all of the 
published results come from different and non-homogeneous, but 
most prospective clinical phase I and II trails. 
Therefore, a direct comparison between the data sets of differ-
ent studies isdifficult. However, even with these limitations of clinical 
use of PRRT, objective responses to the radionuclide therapy are re-
corded from 10% up to 34% of patients. Consider usually advanced 
stage of disease (CS IV), this seems to be quite effective way to 
treat patients with advanced, non-resetable usually progressive 
neuroendocrine neoplastic disease [3–7]. 
Currently most centres used 177Lu DOTATATE. 177Lu is a me-
dium-energy β-emitter with a maximum energy of 0.498 MeV, mean 
0.133 MeV and a maximal tissue penetration of 1.7 mm and mean 
0.23 mm. Its half-life is 162 hours. 177Lu also emits low-energy 
γ-rays at 208 keV and 113 keV with 10% and 6% abundance, 
respectively, which allows somatostatin receptor imaging (SRI) 
and subsequently to assess an internal dosimetry with the same 
therapeutic radiopharmaceutic agent. The shorter β-range of 177Lu 
provides potentially better irradiation of small tumours, in contrast 
to the longer β-range of 90Y which provides more uniform irradiation 
in large volume tumours that may show heterogeneous uptake of 
radiotracer in both diagnostic somatostatin receptor imaging (SRI) 
and also post therapeutic scans. Currently the most widely used 
radiopharmaceutical is 177Lu-DOTA-Tyr3-octreotate (177Lu-DOTATATE 
or 177Lu-octreotate), less common 177Lu DOTATOC [8, 9]. Also, 
only for 177Lu-DOTATATE the clinical efficiency was proved in the 
NETTER-1 phase III randomized trial of 177Lu- DOTATATE vs. 
high-dose Octreotide LAR in patients with non-resectable, progres-
sive, midgut carcinoid tumours [10].
PRRT efficacy
Over past two decades, PRRT with 90Y and 177Lu DOTA SSTA 
proved to be efficient therapy of advanced, non-resectable and 
progressive NEN with tumour responses, based on radiological, 
evaluation, biomarkers reduction as well as clinical symptoms relief, 
improving quality of life (evaluating by standard EORTC quality of 
life questioners (EORTC QLQ C-30 and GI NET21) [11–13].
90Y [DOTA0, Tyr3] octreotide (DOTATOC) has been the most 
widely used radiopeptide in the first decade of PRRT experience. 
The protocols were mostly based on empirical criteria [1–7]. Most 
of schemes, the injection of therapeutic activities, came from es-
calation studies and clinical experiences of the researchers, with 
big differences among protocols. Few centres used fixed dose, 
others used related to body weight or body surface. Also, there 
is discordant between number of cycles and time of intervals be-
tween each cycle of PRRT [3–8]. 
The first studies with 90Y-DOTATOC/TATE or 177Lu DOTATATE 
were conducted in patients with advanced disease, further stud-
ies demonstrated a higher efficacy of PRRT in those with less tu-
mour burden stage. Some studies indicated that the tumour liver 
load, and patient clinical status (PS — performance status, WHO 
or ECOG) are the independent prognostic factor of overall survival 
and predicting factor of PRRT outcome [1, 5, 7, 8]. 
Recent studies have demonstrated that FDG is also a crucial 
parameter in predicting the duration of response to PRRT. Indi-
viduals with positive FDG exhibit a significantly shorter PFS, clear 
evidence that tumour glucose utilization represents a significant 
parameter in predicting therapeutic efficacy [5, 7, 14].
The current strategy of PRRT in advanced, non-resectable, 
often progressive NET indicated more frequent use of radioisotope 
therapy, which was provided by numerous factors including tumour 
volume and the biologic features of the neoplasm. Thus, more 
advanced (aggressive) tumours expressed less somatostatin re-
ceptors (SSTR) and are FDG-positive, increased genetic mutations, 
such as in p53, and are thus less responsive to treatment [14, 15]. 
A further consideration was the localisation of primary NET 
treated by PRRT. Thus, metastases of pancreatic NETs more fre-
quently have radiological (RECIST, WHO or SWOG) response to 
PRRT compare to other types of NETs. Those patients with hormonal 
symptoms of NETs also relapse more rapidly [5–8, 13–15].
However, the only prospective trial proving PRTT efficacy 
is NETTER-1 phase III randomized trial of 177Lu-DOTATATE vs. 
high-dose Octreotide LAR in patients with inoperable, progressive, 
midgut carcinoid tumours. This trial identified that 177Lu-octreotate 
significantly improves PFS in patients with functional as well 
as non-functional tumours (PFS not reached vs. 8.4 months; hazard 
ratio 0.21, with a 79% reduction of the risk of progression). The 
overall number of deaths was also significantly lower in the PRRT 
group (14 vs. 26) [10].
PRRT clinical consideration
Candidates for therapy should be selected based on scin-
tigraphy with 99mTc-HYNICTOC (Tektrotyd®, NCBJ, Polatom PL) 
— somatostatin receptor scintigraphy (SRS) or, more recently, 
using 68Gallium-labeled synthetic SST analogues DOTATOC 
(Somakit®; AAA, CH) or DOTATATE (NETspot®; AAA, CH). Such 
images should indicate an adequate uptake (at least equal to the 
uptake of normal liver) as evidence of adequate expression of 
targetable somatostatin receptors. Somatostatin Receptor Imag-
ing (SRI) evaluation of somatostatin receptor is the most accurate 
noninvasive method to identify and confirm the overexpression of 
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functioning SST receptors. Other methods like immunohistochemis-
try of SST receptors expression, which provides similar information 
at the time of biopsy, are not practical from clinical point of view. 
In fact, that immunohistochemistry, is not as quantitatively accu-
rate as molecular analysis (real time polymerase chain reaction 
RT-PCR and Western blot), which can precisely define the level 
of somatostatin receptors (SSTR) and their functionality due to 
calculation of receptor protein amount [16, 17]. The use of in vivo 
functional SRI methods facilitates the simultaneous evaluation of 
the receptor density and the internalization capacity in real-time 
in all lesions base on single functional imaging approach. When 
evaluating images to determine PRRT selection, it is important to 
exclude false positives. False positives include uptake in the gall 
bladder (for example inflammation), accessory spleens, recent sur-
gical scars (inflammatory infiltrate), previous radiotherapy and any 
other cause of granulomatous or lymphoid (sarcoidosis) infiltrate 
that can mimic the presence of NET tissue [1, 2]. 
The signal typically represents accumulation of inflammatory 
cells which express SST receptors. False negatives should also 
be considered. These are mainly represented by small, sub-centi-
meter lesions, below the resolution limit of the functional imaging 
technique (although this limitation is partially overcome by recent 
advance of PET/CT technology). In addition, certain tumors, such 
as the majority of highly malignant and high grade (Ki-67 > 55%) 
NENs do not express adequate numbers of detectable somatostatin 
receptors [17].
The practical consideration of PRRT in patients with advanced, 
non-resectable NET should include the goal of therapy: carcinoid 
syndrome control resistant to somatostatin analogues, reduction of 
progressive tumour mass or neoadjuvant treatment before surgery 
[1, 2, 5, 8, 12, 18, 19]. 
Another clinical issue is monitoring the results of the therapy. 
Currently, the clinical evaluation of the PRRT is used with evaluation 
of symptoms reduction, improvement in performance status (PS) 
using ECOG or WHO criteria. So far, there is no randomised control 
trails to unified inclusion criteria, except ones used in NETTER-1 
protocol for midgut NET, evaluation form of clinical effect of this kind 
of treatment, through the different protocols are currently used in 
clinical practice [10]. Compare to other randomised trials in onco-
logy the inclusion and exclusion criteria in most published reports of 
PRRT are not quite clear and often inhomogeneous including selec-
tion of patients, previous therapy, stage of disease etc. [3, 4, 6–8]. 
Additional question to be answer is the additional treat-
ments with PRRT. Currently data from NETTER-1 trial shows con-
comitant use of “cold” SST analogues in patients with functional 
tumours. There is still doubt, if somatostatin analogues should be 
used between PRRT cycles also in patients with non-functional 
tumours [2, 12].
Some recent studies have examined the utility of PRRT us-
ing 177Lu DOTATATE with concomitant chemotherapy (CapTem 
— capecitabine and temozolomide). The results indicated bet-
ter objective response rate (ORR), than PRRT or chemotherapy 
alone with accepted toxicity [20]. The concept of simultaneously 
use of different drugs together with PRRT seems to be rational. 
In most clinical trials PFS is a primary end point of the study 
as a surrogate of the improvement of overall survival (OS). The 
other questions addressed is used of adjuvant therapy after PRRT 
as a supportive treatment with SST analogues or targeted therapy 
everolimus — mTOR inhibitors (mammalian target of rapamycin) 
or sunitynib — multitarget tyrosine kinase inhibitor particular in 
those patients with advanced non-resectable, progressive well or 
moderate differentiated pancreatic NET [21, 22]. 
The optimal sequence for using PRRT, chemotherapy, everoli-
mus, and sunitinib will remain to be established in further clinical 
trials. There is only few reports indicated potential used of both 
techniques, so far not as subsequent therapy approach, but as ad-
ditional option after relapse of PRRT [23, 24].
Just another point which is not clear so far is a decision of 
reasonable treatment courses using PRRT. At least two treatment 
cycles should be performed for more sufficient tumour killing by 
high energetic electrons from 90Y or 177Lu. Most centres used several 
injections up to 4 in their standard protocol [3, 4, 6–8, 13, 17, 24]. 
Also, 4 cycles were used in NETTER-1 trial [10]. However, from 
clinical experience we know that the number of courses depend 
on patient clinical status, concomitant disease previous therapy, 
which could influence renal and bone marrow function. In case of 
restricted bone marrow reserve or kidney deterioration the injected 
activity and number of therapy session should be reduced [2, 5, 
12, 13, 17, 24–26].
Currently when 177Lu DOTATATE is routinely used, the sig-
nificant delayed adverse events consider kidney damage and 
myelosupression occur approximately only in 1.4% of patients. 
The meylosupression which is more dramatic in terms of pa-
tient survival, than kidney damage should be consider in those 
patients with initial cytopenia, which is contributed to significant 
haematological toxicity [24–26]. 
The rational use of several courses of PRRT at least 8–9 
weeks each other is related to the recover of bone marrow after 
radioisotope therapy. There is additional need of clarification how 
fast we can back to repeat PRRT after relapse of initial therapy? 
Some reports indicated relatively safe repeat PRRT in patients with 
GEP-NETs after initial PRRT and response on this type of therapy. 
The PFS of repeat therapy was only 13 months (CI ± 95% 9.0–18.0), 
but there was no significant haematological and renal toxicity, 
based on Common Terminology Criteria of Adverse Events — NCI 
(CTCAE ver. 3.0) [26]. 
Before including cytotoxic agents and in case of well or mod-
erate differentiated NET/NEN of pancreatic origin sunitynibe or 
everolimus another therapy option should be used. The way of ad-
ministration is also important . In case of massive liver involvement 
and not significant outside of the liver tumour involvement should 
we prefer i.a. injection of the radiolabelled SST analogues [23]. 
There are only few reports considering intra-arterial PRRT. Initial 
report described use of 90Y DOTALAN in therapy of bulky liver di-
sease after relapse on standard therapy, another report described 
used of 90Y DOATATE [27, 28] The optimal methods will remain to 
be established in clinical trials.
Technique of PRRT administration
PRRT consists of the several times of radiopeptide admi-
nistration. The cumulative activity, fractionated in multiple cycles, 
is able to irradiate the tumour more efficiently, than single dose, 
without surpassing the conventional 25- to 27-Gy absorbed dose 
threshold to the kidneys, which are the dose-limiting organs. Re-
cently, it has been reported that the biologic effective dose (BED) 
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as opposed to the absorbed dose provides a dose threshold value 
that is slightly higher [29].
The rhythm of administration, every 6 to 9 weeks, is based 
on the time that has been determined as necessary to recover 
from potential haematological toxicity [2, 5, 12, 24, 25]. To reduce 
the renal dose of irradiation, patients are prepared to an intra-
venous infusion of positively charged amino acids — AA (lysine 
and arginine), usually at least 25 g AA per therapy. This infusion 
is started 1–3 hours before the radioisotope administration and 
is maintained until 4 to 6 hours after the radioisotope administra-
tion [1, 2, 12, 13]. The infusion has the objective of simultaneously 
hydrating the patients and reducing the renal radioactivity dose by 
providing competitive inhibition of the proximal tubular reabsorption 
of the radiopeptide. The radiopeptide is intravenously administered 
slowly over 20–30 minutes in approximately 50–60 mL of saline 
using infusion pump. In some cases, mild adverse events (AEs) 
are experienced during the administration [2, 5, 12, 17, 24]. These 
mild adverse events (AE) include gastrointestinal symptoms, 
such as a slight nausea, and occasionally, vomiting. These symp-
toms may be related to the AA co-administration, but are controlled 
with appropriate medication (antyemetics) [1, 2].
Tumour response on 90Y DOTA SST analogues 
PRRT
A number of phase I and II trails, retrospective, and most 
prospective oriented at defining the objective response using 90Y 
DOTATOC. In specific classes of diseases, mostly GEP-NET, were 
published in the past 15 years [1, 3, 4]. Most of these trails con-
sider very advanced disease after relapse of standard therapy. In 
this clinical advanced disease led to use PRRT in earlier phases of 
disease because it was evident that with decreased tumor burden 
radiopeptides exhibited a greater efficacy [1, 2, 5, 17]. 
In an initial study, 39 patients with NENs, mostly of gastro-
enteropancreatic (GEP-NET) origin, were treated with 4 cycles of 
90Y DOTATOC with a cumulative activity of 7.4 GBq. Objective 
responses, based on advanced disease radiological response 
according to WHO criteria, were as follows: complete remission in 
2 patients (CR), partial response in 7 patients (PR) and disease sta-
bilization in 27 (SD). Pancreatic NETs (13 patients) showed a better 
objective response (38% PR and CR) than the other classes did [3].
In another multicentre phase I study, including 60 patients af-
fected by GEP NETs were treated with 4 cycles and administered 
6–9 weeks apart. In an initial evaluation of the results published 
in 2002 in 32 evaluable patients, objective responses, accord-
ing to Southwest Oncology Group (SWOG) criteria, consisted in 
about 9% of partial responses and 9% of minor responses [30]. 
In a later analysis of the same population published in 2006 on 58 
assessable patients who were treated with cumulative activities of 
1.7–32.8 GBq, a 57% clinical benefit, including stabilization and 
minor responses, was observed, according to SWOG criteria. A true 
objective response was described in 5% of the patients. The most 
relevant finding of the study was the observed overall survival (OS), 
with a median 37 months and a median progression-free survival 
(PFS) of about 29 months [30]. Characteristically, patients stable 
at baseline had a better overall survival than those who were pro-
gressive at baseline. The extent of disease at baseline was also 
a predictive factor for survival.
The Milan group reported results of two phase I/II studies and 
an evaluation of therapy 141 patients with different NENs. All pa-
tients were treated with a cumulative activity of 7.4–26.4 GBq of 90Y 
DOTATOC. The OR rate was 26%, including CR and PR, according 
to SWOG criteria. Stabilization was seen in 55% of them and DP in 
18%. The median progression free survival (PFS) was 18 months. 
The study indicated that if treated patients had better PS (WHO or 
ECOG) or/and had stable disease before PRRT, those patients had 
better OR and outcome (PR and CR in 32%) compared to those 
who had DP or worse PS (PR and CR in 24%) [31]. Most who 
responded had GEP-NETs. 
A significant observation was the assessment of the objective 
response according to the basal status indicated that individu-
als stable at baseline demonstrated a better outcome (partial and 
complete responses in 32%) than individuals with progressive 
disease (partial and complete responses in 24%). 
American multicentre study of the role of 90Y DOTATOC in 
symptomatic, midgut, advanced, non-resectable NEN conducted 
in 90 patients showed stabilization of tumour mass, according to 
SWOG criteria in 74% of patients, as well as, a significant clinical 
response, including most of the symptoms related to the tumour 
burden and the hormone related clinical symptoms of carcinoid 
syndrome, PFS in this group of subjects was 16 months and OS 
27 months [32].
The one of the pioneers of PRRT, the Basel group published 
the results of their open-label phase II trial in 1,109 patients treated 
with 90Y DOTATOC, divided into multiple cycles of 3.7 GBq/m2 
each. Objective responses (CT), according to RECIST criteria, 
were observed in 378 (34.1%), biochemical response in 172 
(15.5%) and symptomatic response in 329 (29.7%). Improvement 
in overall survival (OS) was related to tumour and symptomatic 
response. The best predictor of OS was the tumour uptake at 
baseline [33].
There are only few reports about the use of 90Y-DOTATATE 
in one of them a group of 60 patients with histologically proven 
GEP-NETs were treated with 4.1–16.2 GBq per patient (mean 
3.7 GBq per therapy). Six months after PRRT completion, 
partial response was registered in 13 patients (23%), while 
the remaining patients showed stable disease (77%). Median 
progression-free survival was 17 months, while the median overall 
survival was 22 months. Haematological AEs WHO grade 3 and 
4 was noted during therapy in 10% of patients and persisted in 
5%. After 24 months of follow-up, renal toxicity grade 2 was seen 
in seven patients, and the authors pointed out the need for care-
ful renal monitoring [7]. Summarized data of outcome after PRRT 
using 90Y DOTATOC is presented in Table 1, after PRRT using 90Y 
DOTATATE [7, 34] and additional clinical use of 90Y DOTALAN [6] 
are presented in Table 2.
The evaluation of results of many trails using PRRT indi-
ces that treatment in a phase of “early” progression rather than 
a “wait-and-watch” approach was more efficacy [1, 2, 5, 12, 13]. 
Overall, it was apparent that PRRT treatment in advanced stage 
disease was substantially less effective. A further considera-
tion was the type of disease being treated. Thus, metastases of 
pancreatic NET/NENs were frequently more amenable to therapy 
compared with other types of NENs. Active secretors tumours with 
bioactive substance production (functional NEN) also tended to 
relapse very rapidly [1, 2, 8, 13, 17]. 
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Table 1. Outcome of PRRT using 90Y DOTATOC, selected publications
Study Type of the tumour No pts Overall response rate OS (median & 
range, months)
PFS (median & range 
months)





Bodei et al. EJNM 2004 Various type of NET 141 26% CR & PR; 55% SD N.R. 18 M
Valkema et al. Semin Nucl Med. 
2006
Various type CS IIIB & IV 58 21%
CR & PR 
37 M (19–54) 14 M
Bushnell et al. JCO 2010 Various „carcinoid” CS IV 90 4% — CR & PR; 74% — SD 27 M 16 M
Imhof et al. JCO 2011 Various NET, CS unclear 1109 34% CR & PR 26 M N.R.
Table 2. Outcome of PRRT using 90Y DOTATOC, selected publications
Study Type of the tumour No pts Overall response rate OS (median & 
range, months)
PFS (median & range 
months)
Virgolini et al. Sem Nucl Med. 
2002
Carcinoid, CS unclear 34 18%
CR & PR
24 M N.R.
Sowa-Staszczak et al. Endo 
Pol 2011
Varius NET, progressive CS IV 32 44%
CR & PR
N.R. N.R.





22 M all 
39 M PR & SD
10 M in DP
17 M all 
24 M PR & SD 
5 M in DP
Peptide receptor radionuclide therapy using 
analogues labeled with 177Lu
Currently most clinical work about PRRT are focused on 
177Lu [DOTA0, Tyr3] octreotate (DOTATATE). This radioisotope 
is a medium-energy β-emitter with a maximum energy of 0.5 MeV 
and a maximal tissue penetration of 2 mm. Its half-life is 6.7 days. 
177Lu also emits low-energy γ-rays at 208 and 113 keV with 10% 
and 6% abundance, respectively, which allows scintigraphy and 
subsequent internal dosimetry with the same therapeutic compound 
[8, 12, 35–38]. The shorter β-range of 177Lu provides better irradia-
tion of small tumours, in contrast to the longer β-range of 90Y which 
allows more uniform irradiation in large tumours that may show 
heterogeneous uptake. In a comparison in patients, it was found 
that the uptake of radioactivity, expressed as a percentage of the 
injected dose of 177Lu-DOTATATE, was comparable with the use 
of 177Lu-DOTATOC in the kidneys, spleen and liver, but was three 
to four times higher in four out of five tumours [35]. Therefore, 
177Lu-DOTATATE has a potential advantage because of the higher 
absorbed doses that can be achieved in most tumours without 
increases in the doses to potentially dose-limiting organs [35, 38]. 
Also, in tumours in the same patients in a therapeutic setting, 
was found that the residence times are in favour of 177Lu-DOTATATE 
in comparison with 177Lu-DOTATOC by a factor of 2.1. [35].
The initial report of using 177Lu DOTATATE was published 
by Kwekkeboom et al. in 2003. This study consists of 35 pa-
tients with GEP-NETs all patients treated with 3.7, 5.6, or 7.4 GBq 
of 177Lu-octreotate, up to a final cumulative dose of 22.2 to 29.6 
GBq, with complete and partial responses in 38% (WHO criteria). 
No serious side effects were observed [36].
The next study the same group analysed responses to 177Lu-DO-
TATATE therapy according to tumour type at 3 months after the last 
therapy cycle in 310 patients [8]. Patients were treated up to an in-
tended cumulative activity of 22.2–29.6 GBq. The overall objective 
tumour response rate including complete remission 2% (CR), PR 28% 
and minor response (MR) 16%, overall there was 46% subjects with 
ORR. SD was noted in another 16% of subjects. Prognostic fac-
tors for predicting tumour remission (CR, PR or MR) as the treatment 
outcome were high uptake on diagnostic Somatostatin Receptor 
Scintigraphy (111In Octreoscan®, NL) and a Karnofsky performance 
score of over 70. A small percentage of patients who had either stable 
disease (SD) or MR at their first two evaluations after therapy, i.e. 
6 and 12 weeks after the last treatment cycle, had a further improve-
ment in categorized tumour response at 6 and 12 months, occur-
ring in 4% and 5% of patients, respectively [8]. The most important 
information from this trail was the impact of PRRT on survival, with 
a median OS over 48 months and a median PFS of 33 months [8]. 
A direct comparison with data obtained from similar patients (in 
the literature) showed a substantial 40-month to 72-month survival 
benefit for PRRT-treated subjects [17]. Although these data are 
not derived from robust/rigorous prospective randomized phase 
III trials, (RCTs) this substantial survival difference in all probability 
reflects a real impact of PRRT as a very efficacy therapeutic ap-
proach in advanced non-resectable NET/NENs. These PRRT data 
compare favorably with other treatments, such as chemotherapy, 
from both the cost/benefit and the tolerability point of view. A catego-
rization of ORR once again indicated that pancreatic NETs tended 
to respond better than other GEP- NETs, although functioning 
tumors (eg, pancreatic gastrinomas) tended to relapse in a shorter 
interval (median time to progression 20 months vs. > 36 in the 
remaining GEP-NETs) [8].
Next prospective trail including 51 patients with advanced 
non-resectable mostly GEP-NETs presented by Milan group. Pa-
tients were treated in a phase I–II study aimed at defining toxicity 
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and efficacy of 177Lu-octreotate. Patients were divided into 2 groups, 
receiving escalating activities, from 3.7 to 5.18 GBq and from 5.18 
to 7.4 GBq, with cumulative activities up to 29 GBq, based on 
dosimetry. PR and CR were observed in 15 patients (32.6%). The 
median time to progression was 36 months, with an overall survival 
of 68% at 36 months. Non-responders and patients with extensive 
tumor involvement had a lower survival [37]. 
There is also recent trail in patients with “poor responding” tu-
mors, including bronchial and gastric NENs. Patients were treated 
with standard 22.2 GBq to 29.6 GBq activities. Despite the limited 
numbers of subjects observed ORR (SWOG criteria) was com-
parable to GEP-NETs. The broncho-pulmonary NETs results were 
5 partial responses, 1 minor response, and 2 stabilizations in 9 pa-
tients. In the gastric tumor group, there was 1 complete response, 
1 minor response, and 2 stabilizations (5 patients). In thymic tumors, 
the series were too small to draw any conclusions [39]. The au-
thors concluded that, contrary to previous findings, PRRT was as ef-
fective in bronchial and gastric NETs as in GEP-NETs [37, 39]. In 
a small group of 21 patients treated with 177Lu-DOTATATE by Garkavij 
et al., 12 were evaluated for objective response using RECIST crite-
ria. PR was found in 5 subjects and SD in another 5 [38].
NETTER-1 phase III randomized control trial (RCT) of 177Lu- 
-DOTATATE vs. high-dose Octreotide LAR in 221 patients with 
non-resectable, progressive, midgut carcinoid tumors identified 
that 177Lu-octreotate significantly improves PFS in patients with 
functional as well as non-functional tumours (PFS not reached vs. 
8.4 months; hazard ratio 0.21, with a 79% reduction of the risk of 
progression) [10]. The overall number of deaths was also signifi-
cantly lower in the PRRT group (14 vs. 26). The response rates of 
18% in the 177Lu-DOTATATE group and 3% in the control group 
were observed (P < 0.001) [10]. Moreover, consistent treatment 
benefits associated with 177Lu-DOTATATE were observed irrespec-
tive of stratification factors and prognostic factors, which included 
levels of radiotracer uptake on somatostatin receptor scintigraphy, 
tumor grade, age, sex, and tumor marker levels NETTER-1 data 
showed that < 10% of patients developed myelosuppression [10].
There are few reports using a salvage protocol with 177Lu-DOTA-
TATE. Patients in progression were enrolled after an initial response 
to PRRT with 177Lu-octreotate, administered using standard cumula-
tive activities (22.2–29.6 GBq). In this series, 32 patients with bron-
chial or GEP-NETs received 2 additional cycles of 177Lu-octreotate, 
with a cumulative activity of 15 GBq. A new objective response 
occurred in 8 patients (2 PR and 6 MR), whereas stabilization 
was identified in another 8 patients. Median time to progression 
(TTP) was 17 months. Both, response rate and duration over time 
appeared lower than during the primary treatment [26]. An example 
of patient with progressive, non-resectable NETG2, Ki-67 = 15%, 
cancer of unknown primary (CUP), after relapse of previous therapy 
including i.v. and i.a. PRRT, current salvage PRRT using 177Lu DO-
TATATE is present on Figure 1.
In second trail the mean cumulative activity was 44.3 GBq 
(30.0–83.7 GBq) consider initial and next PRRT. ORR with CR noted 
in 1 patient (3.0%), PR in 6 patients (18.2%), MR in 1 patient (3.0%), 
SD in 14 patients (42.4%), and PD in 11 patients (33.3%). Median 
PFS from the start of salvage therapy was 13 months. None of the 
patients developed severe nephrotoxicity (grade 3/4) or a myelo-
dysplastic syndrome during follow-up [25].
Protocols combining 177Lu-peptides and 90Y-peptides have 
been considered to take advantage of the different physical 
properties of both 2 radionuclides. In theory, the combination of 
the 2 radioisotopes would allow simultaneous treatment of both 
larger lesions (based on the higher energy and penetration range 
of the particles emitted by 90Y) and small lesions (based on the 
lower energy and penetration range of 177Lu) [40]. Some new al-
gorithms are used like sequential use of 90Y and 177Lu DOTATATE 
(duo) [41] or mix of both radioisotopes (tandem). In the study 
using mix (tandem) PRRT (90Y/177Lu DOTATATE) provided longer 
overall survival than with a single radioisotope (90Y DOTATATE), 
the weak point of this study this was not RCT, and initial group of 
patients treated with 90Y DOTATATE was compare to second group 
those treated with mix [42]. 
Other study using mix 90Y and 177Lu DOTATATE (tandem) 
was reported on limited number of patients, only 26, induced 
objective responses was in 42.3% of patients with metastatic NET 
with a median PFS over 24 months. Patients with carcinoid syn-
drome in 90% showed a symptomatic response or a reduction in 
tumour-associated pain [43]. This relatively new strategy, however, 
have been still be validated in clinical practice in larger series and 
optimal RCT. Furthermore, the previously published studies include 
treatment schemes wherein 177Lu and 90Y were administered us-
ing empirically designed protocols rather than being based on 
individualized dosimetric analyses [17]. 
Another option for more efficient therapy using PRRT is com-
bination of radioisotopes and chemotherapy. The initial report 
comes from Rotterdam. Keeping with recent tendencies in 
oncology, PRRT experiences have been focused toward com-
bination therapies. In particular, combinations of the radiosen-
sitizer chemotherapy agent, capecitabine, with 177Lu-octreotate 
have been undertaken. An initial study in a small group (n 57) 
with progressive GEP-NETs reported encouraging results [44]. 
Patients were treated with 4 cycles of standard activities of 
177Lu-octreotate followed by capecitabine (1650 mg/m2) for 
2 weeks. No severe toxicity, particularly hand-foot syndrome or 
hematological/renal-associated toxicity was evident. Objective 
responses were observed. 
A phase II study of progressive NETs with combining chemo-
therapy and PRRT was performed by Australian group. In their 
initial study 177Lu DOTATATE (7.8 GBq) was used together with 
capecitabine in case of progressive disseminated NEN. The re-
sults of such approach were as follows 24% of complete response 
(CR) and partial response (PR), 70% of stable disease (SD) and 
6% progressive disease (PD). Median progression-free survival 
and median overall survival had not been reached at a median 
follow-up of 16 months (range 5–33 months). Survival at 1 and 2 
years was 91% (95% CI 75–98%) and 88% (95% CI 71–96%) [45]. 
The next study of the same Australian team shows even better 
results using combination of standard activity and protocol includ-
ing mean 4 times administration of 177Lu DOTATATE (7.8 GBq each 
dose) and chemotherapy using capecitabine and temozolomide 
in treating advanced low-grade neuroendocrine tumors (NETs). 
Overall, complete response (CR) was achieved in 15% (95% CI 
3–27); partial response (PR), in 38% (95% CI 22–55); stable disease 
(SD), in 38% (95% CI 22–55); and 3 patients failed to respond to 
the treatment. 
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Figure 1. A 62-year-old male with NETG2 (Ki-67 = 15%) cancer of unknown primary (CUP). After relapse of several treatment approaches 
including chemotherapy, analogues SST therapy, initial i.v. and i.a. PRRT using 90Y DOTATATE, currently, with liver and chest relapse and further 
progression salvage therapy. A. Initial (before present PRRT) Somatostatin Receptor Scintigraphy using 99mTc HYNICTOC (Tektrotyd®; NCBJ, 
Polatom, PL). WB-SPECT (whole body SPECT) image with multiple liver and chest metastasis with high uptake of the radiotracer evaluated 
as Krenning 4; B. PRRT post-therapeutic scan after infusion of 5.55 GBq of 177Lu DOTATATE. Acquired after 12 h, using the same WB-SPECT 
technique to compare with initial SRS scan. There is further liver progression, seen in first post-therapy scan, all lesions with high uptake of 
radiotracer with similar distribution as diagnostic scan; C. Next diagnostic SRS scan 3 months after second PRRT (5.55 GBq 177Lu DOTATATE), 
using 99mTc HYNICTOC (Tektrotyd®; NCBJ, Polatom, PL), WB-SPECT shows at least metabolic stabilization, clinical PR
A B C
Median progression free survival (PFS) was 31 months (95% 
CI 21–33), and median overall survival (OS) has not been reached 
with 90% surviving at 24 months follow-up (range 21–30). Overall 
objective response rate (ORR) in patients with gastroentero-
pancreatic NETs showed CR 16% (95% CI 3–28), PR 41% (95% 
CI 24–58), SD 37% (95% CI 21–54), and PD 6% (95% CI 0–15). 
Response rates were higher in patients with gastro-pancreatic 
NETs than in those with bowel primaries (enteric-NETs); CR 18% 
versus 13%, PR 64% versus 13%, SD 12% versus 67% [46]. 
Summarized data of selected studies with outcome after PRRT us-
ing 177Lu DOTATATE and also selected papers consider outcome after 
PRRT using mix 90Y and 177Lu DOTATATE, also 177Lu DOTATATE with 
capecitabine and temozolamide (CAPTEM) is presented on Table 3.
Just another option is used locoregional therapy together with 
PRRT, which potentially lead to higher efficacies. Radioembolisa-
tion (RE) using resin or glass spheres loaded with 90Y is high ef-
fective way to destroy cancer cells, due to hypervascularity of the 
NEN tumours. Selective internal radiation therapy (SIRT) is kind 
of intravascular brachytherapy. This concept of therapy is rational 
in case of liver dominant disease and heterogenous SST expres-
sion [47]. 
There is an only single report using RE after relapse after PRRT, 
performed as salvage option of therapy. A retrospective analy-
sis of 23 advanced NENs patients, the overall response rates for 
radiologic, biochemical, and symptomatic responses were 30.4%, 
53.8%, and 80%, respectively [48]. The median overall survival 
was 29 months (95% CI ± 95% 4.0–54.0) from the first radioem-
bolization session and 54 months (95% CI ± 95% 47.0–61.0) from 
the first PRRT cycle. The key point of this option was the safe use 
of RE after initial PRRT. The mean previous cumulative activity of 
177Lu-DOTATATE was 31.8 GBq. The mean cumulative treatment 
activity of RE with 90Y microspheres was 3.4 ± 2.1 GBq. It should 
be mentioned that any previous external radiotherapy is con-
traindicated to RE, except of PRRT. In clinical settings probably 
RE could be used before PRRT, in those cases with bulky liver 
disease with heterogeneous receptor expression to kill cancer 
cells without SST expression, potentially select clones with over-
expression of SST [14].




Radiolabeled somatostatin analogues provide a means of 
delivering targeted radiation with a high therapeutic index to 
tumors that overexpress somatostatin receptors. The clinical 
data from nonrandomized multiple trials, as well as, from the 
NETTER-1 randomized control trial have shown high response 
rates and long durations of median progression-free survival in 
heterogeneous patient populations with gastro-entero-pancreatic 
neuroendocrine tumors (GEP-NET) with limited adverse events ef-
fects (AEs). 
Radionuclide therapies with radiolabeled somatostatin 
analogues provide symptomatic benefit and increase survival in 
patients with metastatic NEN, particular GEP-NETs and are a rea-
sonable option for treatment NEN patients.
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